You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

HER-2 ADC

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma Trial (SHR-A1811, Ramucirumab / Paclitaxel/

Not yet recruiting
  • HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
  • SHR-A1811
  • Ramucirumab / Paclitaxel/ Docetaxel/ Irinotecan
  • (no location specified)
Nov 6, 2023

Colorectal Cancer Trial (Anti-HER2 ADC)

Not yet recruiting
  • Colorectal Cancer
  • Anti-HER2 ADC
  • (no location specified)
Oct 12, 2022

Advanced Breast Cancer Trial (Disitamab vedotin)

Not yet recruiting
  • Advanced Breast Cancer
  • Disitamab vedotin
  • (no location specified)
Apr 16, 2023

HER2-positive Advanced Breast Cancer Patients Treated With ADC

Recruiting
  • Breast Cancer
  • HER2 expression of circulating tumor cells
  • Beijing, Beijing, China
    The Fifth Medical Center of PLA General Hospital
Apr 18, 2023

HER2-low Advanced Breast Cancer Patients Treated With ADC

Recruiting
  • Breast Cancer
  • HER2 expression of circulating tumor cells
  • Beijing, Beijing, China
    The Fifth Medical Center of PLA General Hospital
Apr 18, 2023

Non-muscle Invasive Bladder Cancer Trial in Chengdu (RC48-ADC)

Not yet recruiting
  • Non-muscle Invasive Bladder Cancer
  • Chengdu, Sichuan, China
    West China Hospital
Aug 10, 2023

Colorectal Cancer Trial in Hangzhou (RC48-ADC plus Bevacizumab)

Not yet recruiting
  • Colorectal Cancer
  • RC48-ADC plus Bevacizumab
  • Hangzhou, Zhejinag, China
    The second affiliated hospital of Zhejiang University
Mar 24, 2023

Breast Tumor, Breast Cancer, Breast Tumors Trial in Shanghai (Dalpiciclib, Pyrotinib, SHR-A1811)

Not yet recruiting
  • Breast Neoplasm
  • +9 more
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cancer Center Shanghai, China, 200032
Oct 13, 2022

Upper Urinary Tract Urothelial Carcinoma, Kidney Preservation, HER-2 ADC Trial in Shanghai (RC48 Combined With Tislelizumab)

Recruiting
  • Upper Urinary Tract Urothelial Carcinoma
  • +3 more
  • RC48 Combined With Tislelizumab
  • Shanghai, Shanghai, China
    Ethics Committee of Shanghai Renji Hospital
Jun 20, 2023

Solid Tumor Trial (Disitamab vedotin)

Not yet recruiting
  • Solid Tumor
  • Disitamab vedotin
  • (no location specified)
Jul 10, 2023

Gastric Cancer Trial in Beijing (RC48-ADC, Herceptin, Toripalimab)

Not yet recruiting
  • Gastric Cancer
  • Beijing, China
    Beijing Cancer Hospital
Aug 7, 2023

NSCLC Trial in Shanghai (RC48-ADC, Pyrotinib)

Not yet recruiting
  • Non-small Cell Lung Cancer
  • Shanghai, Shanghai, China
    Shanghai Pulmonary Hospital
Feb 16, 2023

NMIBC Trial in Beijing (RC48-ADC in Combination with gemcitabine)

Recruiting
  • NMIBC
  • RC48-ADC in Combination with gemcitabine
  • Beijing, Beijing, China
    Peking University First Hosptital
Jul 10, 2023

Biliary Tract Cancer Trial (RC48-ADC, Envafolimab)

Not yet recruiting
  • Biliary Tract Cancer
  • (no location specified)
Jun 9, 2022

Breast Tumors Trial in Beijing, Nanjing, Changsha (Disitamab Vedotin, Toripalimab)

Not yet recruiting
  • Breast Neoplasms
  • Beijing, Cancer Hospital Chinese Academy Of Medical Sciences, China
  • +2 more
Oct 23, 2023

Salivary Gland Tumors Trial in Beijing (RC48-ADC)

Recruiting
  • Salivary Gland Tumors
  • Beijing, Beijing, China
    Peking Union Medical College Hospital
Oct 28, 2022

Advanced Solid Tumors, Metastatic Solid Tumors Trial (JSKN003)

Not yet recruiting
  • Advanced Solid Tumors
  • Metastatic Solid Tumors
  • (no location specified)
Aug 10, 2022

Carcinoma, Upper Tract Urothelial Carcinoma, UTUC Trial in Nanjing (RC48-ADC and JS001)

Recruiting
  • Carcinoma
  • +2 more
  • RC48-ADC and JS001
  • Nanjing, Jiangsu, China
    Jinling Hospital, Affiliated Hospital of Medical School, Nanjing
Jun 15, 2023

Breast Cancer Trial in Shanghai (SHR-A1811, TROP2 ADC)

Active, not recruiting
  • Breast Cancer
  • Shanghai, China
    Fudan University Shanghai Cancer Center
Apr 11, 2023

Gastric Cancer Trial in Beijing (RC48-ADC, RC98-ADC)

Not yet recruiting
  • Gastric Cancer
  • Beijing, Beijing, China
    Remegen
Aug 21, 2022

Breast Cancer Trial (Trastuzumab Deruxtecan)

Not yet recruiting
  • Breast Cancer
  • Trastuzumab Deruxtecan
  • (no location specified)
Jul 10, 2023

Advanced Gastroesophageal Adenocarcinoma Trial in Beijing (RC48-ADC, S-1)

Recruiting
  • Advanced Gastroesophageal Adenocarcinoma
  • Beijing, China
  • +2 more
Sep 14, 2022

Carcinoma, Squamous Cell of Head and Neck, NSCLC, Ovarian Tumors Trial (disitamab vedotin)

Not yet recruiting
  • Carcinoma, Squamous Cell of Head and Neck
  • +3 more
  • disitamab vedotin
  • (no location specified)
Aug 15, 2023

Advanced Breast Cancer Trial in China (RC48-ADC 1.5 mg/kg (HER2 Positive), RC48-ADC 2.0 mg/kg (HER2 Positive), RC48-ADC 2.5

Active, not recruiting
  • Advanced Breast Cancer
  • RC48-ADC 1.5 mg/kg (HER2 Positive)
  • +3 more
  • Beijing, Beijing, China
  • +3 more
Jan 7, 2022

Gynecological Malignancy Trial in Beijing (RC48-ADC)

Recruiting
  • Gynecological Malignancy
  • Beijing, Beijing, China
    Chinese Academy of Medical Sciences Cancer Hospital
Jan 6, 2022